Publications by authors named "Markqayne Ray"

Claim this Profile
V
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.
Miguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, Markqayne D Ray, Yael A Rodriguez-Guadarrama

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.
Olalekan O Oluwole, Sally W Wade, Nathaniel J Smith, Tomas Spousta, Jenny Kim, Markqayne Ray

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Lori A Leslie, John H Baird, Ian W Flinn, Michael Tees, Daanish Hoda, Markqayne Ray

Am J Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan.
John G Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States.
Anik R Patel, Bradley Kievit, Ken Hasegawa, Markqayne Ray, Rishika Sharma

MDM Policy Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.
Frederick L Locke, Graeme Ball, Markqayne D Ray, Tony Li, Eve H Limbrick-Oldfield

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis.
Olalekan O Oluwole, Markqayne D Ray, Hanxiao Ma, Rishika Sharma, Anik R Patel

Transplant Cell Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.
Eve H Limbrick-Oldfield, Steve Kanters, Markqayne D Ray, Timothy Best, Madhu Palivela

EJHaem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.
Markqayne Ray, Jean-Gabriel Castaigne, Alexandra Zang, Anik Patel, Elizabeth Hancock

Adv Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
Markqayne D Ray, Steve Kanters, Sara Beygi, Timothy Best, Jacob Wulff

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States.
Olalekan O Oluwole, Markqayne D Ray, Katherine L Rosettie, Graeme Ball, Jorge Jacob

Value Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes.
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, Zhen-Huan Hu, Markqayne Ray

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade

Expert Rev Anticancer Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Olalekan O Oluwole, Markqayne D Ray, Richard M Zur, Cheryl P Ferrufino, Brett Doble

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen

Clin Lymphoma Myeloma Leuk· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Olalekan O Oluwole, Markqayne D Ray, Neil Davies, Rory Bradford, Calum Jones

J Med Econ· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims.
Markqayne Ray, Kavita Gandhi, Keshia Maughn, Amit G Pandya

JID Innov· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population.
Arash Mostaghimi, Wei Gao, Markqayne Ray, Lauren Bartolome, Travis Wang

JAMA Dermatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States.
Wei Gao, Arash Mostaghimi, Kavita Gandhi, Nicolae Done, Markqayne Ray

J Med Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Markqayne D Ray

Expert Rev Anticancer Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata.
Kavita Gandhi, Morgan E Shy, Markqayne Ray, Moshe Fridman, Shailja Vaghela

Dermatol Ther (Heidelb)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States.
Moshe Fridman, Markqayne Ray, Kavita Gandhi, Morgan E Shy, Arash Mostaghimi

Adv Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.
Markqayne Ray, Elyse Swallow, Kavita Gandhi, Christopher Carley, Vanja Sikirica

J Health Econ Outcomes Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States.
Arash Mostaghimi, Kavita Gandhi, Nicolae Done, Markqayne Ray, Wei Gao

J Manag Care Spec Pharm· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Short- and Long-Term Burden of Acute Pancreatitis in the United States: A Retrospective Cohort Study.
Shibani Pokras, Markqayne Ray, Shan Zheng, Yao Ding, Chi-Chang Chen

Pancreas· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis